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Abstract 
Background: Hereditary transthyretin amyloidosis (hATTR), alias ATTR variant (ATTRv) is a severe and disabling dis-
ease causing sensory and motor neuropathy, autonomic dysfunction, and cardiomyopathy. The progressive decline 
of patient’s functional autonomy negatively affects the patient’s quality of life and requires increasing involvement 
of relatives in the patient’s daily life. Family caregiving may become particularly demanding when the patient is no 
longer able to move independently. This study is focused on the psychosocial aspects of ATTRv from the patient and 
relative perspectives. In particular, it explored: the practical and psychological burdens experienced by symptomatic 
patients with ATTRv and their key relatives and the professional and social network support they may rely on; whether 
burden varied in relation to patients’ and relatives’ socio-demographic variables, patients’ clinical variables, and 
perceived professional and social network support; and, any difference in burden and support between patients and 
their matched relatives.
Methods: The study was carried out on symptomatic patients included in the ATTRv Italian national registry and liv-
ing with at least one adult relative not suffering from severe illness and being free from ATTRv symptoms. Patients and 
relatives’ assessments were performed using validated self-reported tools.
Results: Overall, 141 patients and 69 relatives were evaluated. Constraints of leisure activities, feelings of loss and 
worries for the future were the consequences of ATTRv most frequently reported by patients and relatives. Both in 
patients and their relatives, the burden increased with the duration of symptoms and the level of help in daily activi-
ties needed by the patient. In the 69 matched patient-relative pairs, the practical burden was significantly higher 
among the patients than among their relatives, while the psychological burden was similar in the two groups. Moreo-
ver, compared to their relatives, patients with ATTRv reported higher levels of professional and social network support.
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Background
Hereditary transthyretin amyloidosis (hATTR), alias 
ATTR variant (ATTRv) is a severe and disabling disease 
causing sensory and motor neuropathy, autonomic dys-
function, and cardiomyopathy [1]. This disease is present 
worldwide, with the highest prevalence in Northern Por-
tugal, Northern Sweden, Japan, Majorca and Cyprus [2–
5]. ATTRv has an autosomal dominant transmission due 
to missense mutations in the TTR gene, located on chro-
mosome 18. Mutated protein monomers aggregate to 
form amyloid fibrils, which precipitate in different tissues 
causing dysfunction, such as peripheral nerves, heart, 
gastrointestinal tract, kidney, and eye. Average survival 
from disease onset varies from 6 to 12 years and cardiac 
involvement is often the cause of death [6]. The disease 
is classified on the basis of age at onset, and symptoms 
before the age of 50 distinguish early from late onset 
ATTRv [6]. The course varies in relation to the type of 
mutation and age of onset. Late-onset patients with com-
mon mutation Val30Met (Table  1) from non-endemic 
areas have different phenotype from early-onset cases 
from endemic foci in Portugal and Japan, since these 
patients tend to manifest loss of all sensory modalities, 
mild autonomic dysfunctions, and heart failure with mas-
sive cardiac amyloid deposition. If patients are untreated, 
late-onset Val30Met patients from non-endemic areas 
have much shorter mean survival time than early-onset 
Val30Met patients from endemic foci [4, 7, 8]. Sympto-
matic treatment requires a multidisciplinary approach 
addressing heart manifestations, orthostatic hypotension, 
gastrointestinal disorders with weight loss, and neuro-
pathic pain. For two decades, liver transplantation has 
been the only treatment for halting or slowing amyloid 
deposition in target organs. Since 2011, tafamidis meglu-
mine has been used to slow the progression of the disease 
in neuropathic patients. More recently, two innovative 
and very effective gene silencing therapies have reached 
the market [9].
The progressive decline of neurological functions, 
which is variably associated with disabling cardiologi-
cal and dysautonomic symptoms, negatively affects the 
patient’s quality of life and requires increasing involve-
ment of relatives in the patient’s daily life. Family car-
egiving may become particularly demanding when the 
patient is no longer able to move independently. In the 
late stages of the disease full-time assistance and hos-
pitalization may be necessary. While burden of care 
has been extensively explored in mental and neuro-
logical diseases [10, 11], few studies have specifically 
investigated the practical and psychosocial difficul-
ties experienced by patients with ATTRv and their 
families. Available data reveal that patients with this 
disease have difficulties in marital relationships and 
social life and fear of losing their functional autonomy 
and becoming dependent on family for help [12–14]. 
Worsening symptoms and disease-related disability 
often led to inability to work, and they contributed to 
feelings of frustration and sadness [14]. Furthermore, 
these patients sometimes perceive to be discriminated 
against and negatively judged by others if they plan 
to have children [15]. Moreover, both patients with 
ATTRv and their families are more vulnerable to emo-
tional stress and psychopathology during their lifetimes 
[16, 17], and they have poorer quality of life than the 
general population [18–20]. In at-risk relatives, signifi-
cant long-term psychosocial burden and fear of death 
have also been reported [17, 20, 21]. These studies 
have several weaknesses limiting the generalizability 
of their results. Some studies have small sample sizes 
and were conducted using a qualitative design [14, 20, 
21], a methodology which is difficult to apply in routine 
clinical settings. Furthermore, only a few studies have 
examined the burden of care both from the patient’s 
and the relative’s perspective [12, 18, 20], and none 
has specifically examined the impact of professional 
or social support on the patient’s or relative’s burden. 
The lack of representative data on the burden in ATTRv 
makes it more difficult to develop ad hoc supportive 
interventions for patients and their families.
In the period from 2016-2019, within the framework 
of the Telethon National Program for clinical research, a 
study on ATTRv was carried out in Italy. The study aimed 
to create a national registry collecting clinical, treatment-
related, and genetic information of the disease [22, 23]. 
Moreover, the study investigated the burden of care and 
the professionals and social support in a large sample of 
symptomatic patients and their key-relatives, using vali-
dated, self-reported questionnaires. To our knowledge, 
this is the first study including both patients and relatives’ 
psychosocial data carried out at national level.
Conclusions: These results show that ATTRv is a disease affecting quality of life of both patients and their families. 
Supporting interventions should be guaranteed to patients, to facilitate their adaptation to the disease, and to their 
families, to cope as best as possible with the difficulties that this pathology may involve.
Keywords: Hereditary transthyretin amyloidosis, ATTRv, Burden, Professional support, Social network support, 
Caregiving
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This paper is focused on the psychosocial aspects of 
ATTRv from the patient and relative perspectives. In 
particular, we explored: (a–b) the practical and psycho-
logical burdens experienced by symptomatic patients 
with ATTRv and their key relatives and the professional 
and social network support they may rely on; (c) 
whether burden varied in relation to patients’ and rela-
tives’ socio-demographic variables, patients’ clinical 
variables, and perceived professional and social net-
work support; d) any difference in burden and support 
between patients and their matched relatives.
Table 1 Patients and relatives socio-demographic characteristics and patients’ clinical variables
Mutation nomenclature follows the traditional classification which refers to the TTR protein (NCBI Reference Sequence: NP_000362.1; chromosome 18, NC_000018.10) 
without the first 20 amino acids of the leader peptide. For example, Val30Met corresponds to p.(Val50Met) if one follows the Human Genome Variation Society (HGVS) 
nomenclature (https:// www. hgvs. org/ conte nt/ guide lines)
Patients (N = 141) Relatives (N = 69)
N % N %
Socio-demographic characteristics
 Gender
  Males 106 75.2 15 21.7
  Females 35 24.8 54 78.3
 Age, mean ± SD 66.1 ± 11.09 57.2 ± 11.8
 Marital status
  Free 34 25.2 9 10.5
  Married 101 74.8 60 89.6
 Education
  Primary school 18 14.3 10 14.7
  Secondary school 42 33.3 14 20.6
  High school 44 34.9 32 47.1
  University 22 17.5 12 17.7
 Employed, yes 41 29.5 32 47.1
 Relationship with the patient –
  Spouse 51 75.0
  Other 17 25.0
 Daily hours spent in caregiving, mean ± SD – 8.1 ± 9.7
Clinical variables
 Mutation
  Val30Met 39 27.6
  Phe64Leu 33 23.4
  Glu89Gln 25 17.7
  Ile68Leu 14 9.9
  Val122Ile 7 5
  Tyr78Phe 7 5
  Thr49Ala 6 4.3
  Other (n. 9) 10 7.1
 Phenotype –
  ATTRv-PN 111 78.7
  ATTRv-CM 30 21.3
 ATTRv stage –
  0 6 4.3
  1 75 53.2
  2 42 29.8
  3 18 12.8
Age at symptom onset, mean ± SD 59.8 ± 11.8 –
Length of symptom in years, mean ± SD 6.2 ± 4.2 –
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Methods
Study design and procedures
The study was carried out in ten clinical centres located 
throughout Italy (five in Northern, three in Central and 
two in Southern Italy). All centres were multidisciplinary, 
but eight were coordinated by a neurologist, one by a car-
diologist and one by an internist. An informatics tech-
nology platform dedicated to the ATTRv Registry was 
developed and became effective in 2017. In the period 
from June 2017-November 2019, patients and their key 
relatives (i.e., the relative most involved in the patient’s 
daily assistance) who met the below-mentioned selec-
tion criteria were contacted consecutively and invited to 
participate in the study. Patient selection criteria were the 
following: being included in the ATTRv National Regis-
try; being symptomatic for ATTRv; living with at least 
one adult relative. There were no age restrictions. Key-
relative selection criteria were the following: age between 
18 and 80 years; not suffering from illness requiring long-
term intensive care; being free from ATTRv symptoms.
During a scheduled follow-up visit, each eligible patient 
who gave written informed consent to participate in the 
study was invited to complete: (a) the patient version of 
the Problems Questionnaire (PPQ) [24, 25]; (b) the Social 
Network Questionnaire (SNQ) [25, 26]; (c) the ATTRv 
non-pharmacological Patient Care Schedule (ATTRv-
PCS). At the same occasion, each eligible key relative who 
agreed to participate and signed an informed consent 
was asked to complete: (a) an ad-hoc family socio-demo-
graphic schedule; (b) the family version of the Prob-
lems Questionnaire (FPQ); (c) SNQ (data not reported 
in this paper); (d) the ATTRv-Family Support Schedule 
(ATTRv-FSS). Patient and relative socio-demographic 
characteristics were collected by ad hoc schedules. The 
above-mentioned instruments were self-administered in 
the presence of a trained researcher. Participants did not 
receive any financial or other incentives for their partici-
pation in the study. Furthermore, information on current 
phenotype (predominantly PolyNeuropathy, ATTRv-
PN; predominantly CardioMyopathy, ATTRv-CM), type 
of mutation, age at the onset of symptoms, and ATTRv 
stage (stage 0, subjects asymptomatic for neuropathy, but 
showing only cardiomyopathy; stage 1, symptomatic neu-
ropathy with unimpaired walking; stage 2, need of mono- 
or bilateral walking assistance; stage 3, patient confined 
to a wheelchair [27] was drawn from the ATTRv National 
Registry.
The study protocol was approved by the Ethics Com-
mittee of the University of Messina (coordinating centre), 
and by the Local Ethics Committee of each participating 
centre. The study was performed in accordance to the 
ethical standards laid down in the 1964 Declaration of 
Helsinki and its later amendments.
Instruments descriptions
Problems Questionnaire: the patient-version PPQ con-
tains the same items as the family-version FPQ but refor-
mulated to refer to the patient’s first-person experience. 
The tool explores: (a) the help needed by the patient in 
performing daily activities and adhering to care (5 items); 
(b–c) the support provided by health professionals (5 
items) and their social network in clinical emergencies 
(2 items); (d–e) the practical and psychological burden of 
care (9 items and 7 items, respectively). Items are rated 
on a 4-level scale from 1 “never” to 4 “always” (sections 
d–e) and from 1 “not at all” to 4 “completely” (remain-
ing sections). The reference period is the last 2 months 
except for sections b–c which do not include a specific 
reference period. An average subscale’ score is derived 
across the valid scores of the items included in each sub-
scale. The questionnaire also contains additional sections 
on the economic costs of care, the respondent’s percep-
tions of the illness as a condition also having positive 
aspects, and an open-ended question where respondents 
can offer suggestions to improve the condition of patients 
with ATTRv and their relatives. Cronbach’s alphas values, 
measured in this study samples, were acceptable (a to e 
subscales: from .70 to .92 in the PPQ and from .65 to .93 
in the FPQ).
Social Network Questionnaire: the SNQ is a self-
reported tool exploring the respondent’s: (a) quantity 
and frequency of social contacts (4 items); (b–d) percep-
tion of practical and psychological support received from 
social network and the partner (3 items, 4 items, and 2 
items, respectively). Items are rated on a four-level scale, 
from 1 “Never” to 4 “Always”. In this study, Cronbach 
alphas of the SNQ subscales ranged from .65 to .73 in 
the patient sample and from.66 to .81 in the relative sam-
ple. Both the PPQ/FPQ and the SNQ were administered 
in their entirety, but, as this study is based on PPQ/FPQ 
section a–e and the suggestions section, SNQ items were 
not reported here.
ATTRv-non-pharmacological Patient Care Schedule 
(ATTRv-PCS): this schedule contains seven “Yes/No” 
items on rehabilitative treatments, professional support, 
self-help and association support, and economic benefits 
received by the patient in the previous 12 months.
ATTRv-Family Support Schedule (ATTRv-FSS): this 
schedule contains five “Yes/No” items on the support that 
key relatives have received from professionals, self-help 
groups, and associations in the previous 12 months.
Statistical analysis
Frequencies and percentages were calculated for categor-
ical and ordinal variables describing: socio-demographic 
characteristics of patients and their key relatives (sex, 
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marital status, level of education, current employment, 
relationship with the patient); patients’ clinical features 
(type and stage of ATTRv); help needed by the patient in 
daily activities and care (PPQ and FPQ a subscale items); 
burden (PPQ and FPQ d-e subscales items); professional 
and social support (PPQ and FPQ b-c subscales items). 
Means and standard deviations (SD) were computed for 
continuous variables as patients’ and key-relatives’ ages, 
relatives’ daily hours dedicated to patient’s care, patients’ 
length of illness, and for burden and support subscale 
scores (PPQ and FPQ a-e sections).
In each group (patient group and relative group), 
Spearman’s r coefficient was computed to investigate 
the relationships of practical and psychological burden 
(PPQ/FPQ d-e subscales, respectively) with patients’ and 
relatives’ age, patients’ duration of illness, level of help 
needed in daily activities (PPQ/FPQ subscale a mean 
score, respectively), and professional and social network 
support (PPQ/FPQ b-d subscales mean scores, respec-
tively). ANOVA test was performed to explore the asso-
ciations of burden with respondent’s sex, patient’s type 
of ATTRv, and supportive interventions (ATTRv-PCS 
and ATTRv-FSS items). T-test for paired data was used 
to investigate differences in burden and professional and 
social network support among patients and their par-
ticipating relatives. Statistical significance was set at p < 
0.05. Analyses were performed by using SPSS 21.0.
Results
Sample characteristics
Of the 143 eligible patients and their key-relatives who 
were consecutively contacted, 141 patients and 69 key-
relatives agreed to participate in the study and were 
assessed (refusal rates: 0.01% and 51%, respectively. 
Patients’ refusal reasons: 2 unknowns. Relatives’ refusal 
reasons: 25 unavailable to accompany the patient to the 
clinical examination, 9 lack of interest in the study, 38 
unknown). The 69 patients whose key-relatives par-
ticipated were comparable with the 72 patients whose 
key-relatives did not with respect to the main socio-
demographic variables (sex, age, occupation) except 
for marital status (60/69 married patients among those 
whose relatives participated vs. 42/66 married patients 
among those whose relatives were not assessed, χ2 = 8.6, 
df 1, p < .005), and with respect to the main clinical char-
acteristics (duration of symptoms, phenotype and FAP 
stage) except for help needed in daily activities (mean 
score ± sd: 2.0 ± 1.0 vs. 1.6 ± 1.1, t = 2.1, df 139, p < 
.03). The 141 participating patients were on average 66.1 
(11.09 SD) years old and symptomatic on average for 6.2 
(4.2 SD) years (Table 1). One hundred and eleven (78.7%) 
patients suffered from ATTRv-PN, and 30 (21.3%) from 
ATTRv-CM. Fifty-three percent of the patients had a 
predominantly sensory neuropathy affecting their lower 
limbs and walked without any help (stage 1: n. 75); 29.8% 
needed help walking (stage 2: n. 42), and 12.8% were in 
wheelchairs (stage 3: n. 18). Fifty percent of patients said 
they needed help to get around and 44.7% needed help 
to visit their doctor and take medications in the previous 
2 months (see Additional file 1: Table S1). Twenty-eight 
percent of patients attended rehabilitation programs, 
32.4% had attended informative sessions on ATTRv, 
2.9% had received psychological support, and 12.1% had 
received economic benefits (Fig. 1).
Of the 69 participating key relatives, most were female 
and spouses (Table 1), highly educated and not employed. 
Relatives stated that they spent on average 8.1 (9.7 SD) 
daily hours in patient caregiving over the previous 2 
months (note: 12 relatives stated that they were 24-hour/
day involved in the patient’s assistance). In particular, 
60.9% of the relatives stated that in the previous 2 months 
the patient had needed their help to make medical vis-
its or take medication, and 59.4% stated that the patient 
needed their help to get around (see Additional file  1: 
Table S1). Thirty-three percent of relatives had attended 
informative sessions on ATTRv, 3.0% had received psy-
chological support and 7.5% had received help from fam-
ily/patient associations (Fig. 1).
Practical and psychological burden and perception 
of professional and social network support in patients 
with ATTRv and their relatives
The practical consequences of ATTRv most frequently 
reported by patients with respect to the previous 2 
months concerned the neglect of hobbies and leisure 
time activities (72.9 % of patients) and awakening during 
the night (69.1%). Sixty-seven percent of patients stated 
that they had difficulties in carrying out usual work or 
household activities due to their own health condition. 
As far as the psychological burden, 80.6% of patients 
felt worried for the future of other family members (see 
Additional file 1: Table S2), 77.7% had feelings of loss and 
66.0% thought that if there had no family members, no 
one would have taken care of him/her. Sixty percent of 
patients stated they had cried or felt depressed in the past 
2 months. As far as the support that patients received 
from professionals and their social networks (see Addi-
tional file 1: Table S3), most patients reported receiving 
adequate information from their clinicians on ATTRv 
(87.9%) and its treatments (85.6%). Moreover, 44.3% were 
completely confident they would receive professional 
help in a crisis situation. Sixty-nine percent of patients 
were sure that their friends and relatives would definitely 
help them in the case of clinical emergencies.
Regarding the condition of the 69 participating rela-
tives, 60.9% stated that they had to neglect their hobbies 
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due to the patient’s condition, 60.7% had difficulties in 
going on Sunday outings and 59.3% in going for holidays 
(see Additional file 1: Table S4). Seventy-eight percent of 
relatives had feelings of loss, and 75.0% felt worried for 
the future of other family members. Sixty-four percent of 
relatives thought the family was the only source of help 
available to the patient. Fifty-nine percent of relatives 
stated they had cried or felt depressed due to the patient’s 
condition in the past 2 months. Thirty-eight percent of 
relatives reported they were sure they would receive pro-
fessional help in an emergency concerning the patient, 
and the majority of relatives believed that they had 
received adequate information from clinicians on the dis-
ease and its treatments (72.1% and 77.9%, respectively). 
Forty-six percent of the relatives felt their friends would 
definitely help them in the event of patient’s emergencies 
(see Additional file 1: Table S5).
Relationships of burden with socio‑demographic 
and clinical variables and professional and social support 
in patients and relatives’ groups
In the sample of 141 patients, the practical and psycho-
logical burden increased in relation to the patient’s level 
of help needed in daily activities and weakly in relation 
to the duration of symptoms (Table 2). The practical bur-
den was higher among patients with more severe ATTRv 
stages and the psychological burden was higher among 
patients with ATTRv-PN vs. ATTRv-CM. The bur-
den was higher among patients receiving rehabilitative 
interventions and among patients who had attended 
informative sessions on the disease in the last year.
In the sample of 69 relatives, the practical and psycho-
logical burden were higher in relatives with lower social 
support for patient’s emergencies, in relatives who were 
more involved in providing daily help to the patient, and 
weakly in relatives of patients with a longer duration of 
symptomatic ATTRv (Table 2). Furthermore, the psycho-
logical burden was higher among female vs. male rela-
tives, and among relatives of patients with ATTRv-PN vs. 
ATTRv-CM.
Paired sample comparisons of burden and support
The comparisons of burden and support between the 69 
matched patient-relative pairs are reported in Fig. 2. The 
analyses revealed that the practical burden was signifi-
cantly higher among the patients than among their key 
relatives, while the psychological burden was similar in 
the two groups. Moreover, compared to their relatives, 
patients with ATTRv reported higher levels of profes-
sional and social network support.
Participants’ recommendations on how to improve 
the condition of patients with ATRv and their relatives
Recommendations on how to improve the conditions of 
patients with ATTRv and their families were given by 61 
patients and 32 relatives. In particular, 26.2% of patient 
and 25.0% of relatives suggested to improve the qual-
ity of care (for instance, through the implementation of 
local health centres covering all clinical and rehabilitative 
Rehabilitave       Informave         Genec       Psychological        Family        Economic
therapies           sessions on      counselling        support            and user      benefits
illness and                                                          associaons











Fig. 1 Non-pharmacological interventions and support received by ATTRv patients and their relatives (N:69) in the past year. Black square, patients; 
grey square, key-relatives
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needs of patients with ATTRv, and the provision of at-
home treatments and practical support). Moreover, 
22.9% of patients and 37.5% of relatives recommended 
providing more psychological support and informa-
tion to patients and their families, and 34.4% outlined 
the importance of investing more in research into treat-
ments. Other recommendations were: providing educa-
tion on ATTRv to health professionals, particularly GPs 
(8.2% and 3.1%), simplifying bureaucratic procedures 
and providing economic support to the patients (4.9%), 
promoting sensitization initiatives about ATTRv for the 
public (1.6% and 3.1%), and setting up self-help groups 
throughout Italy (1.6% and 3.1%).
Discussion
This is the first study carried out in Italy that has system-
atically explored the difficulties experienced by patients 
with ATTRv and their families as well as the professional 
and social resources on which patients and families may 
rely. The large sample size of patients,   recruited in 10 
clinical centers located in different geographical areas 
of Italy,   makes these data representative of the national 
situation and useful for comparisons with the burden in 
other countries and in other rare diseases. These data 
could be also useful in the development of ad-hoc sup-
portive interventions for patients with ATTRv and their 
families. Moreover, since the patients are included in 
Table 2 Relationships of burden with socio-demographic and clinical variables and professional and social support
a p < .05; bp < .01; cp < .005; dp < .0001
Practical burden Psychological burden
Patients group
 Help to patient in daily activities and care, r value .63d .54d
 Duration of symptoms, r value .26c .22b
 ATTRv stage, mean (sd)
  0 1.4 (0.5) –
  1 2.0 (0.7) –
  2 2.2 (0.4) –
  3 2.3 (0.7) –
  F, df 3.5; 3, 137 a –
ATTRv type, mean (sd)
  PN – 2.1 (0.7)
  CM – 1.8 (0.5)
  F, df – 5.2; 1,139a
Rehabilitative treatments, mean (sd)
  Yes 2.6 (0.6) 2.5 (0.6)
  No 1.9 (0.7) 1.9 (0.6)
  F, df 26.1; 1,  137d 34.0; 1,137d
Informative sessions on the disease, mean (sd)
  Yes 2.3 (0.7) 2.3 (0.7)
  No 1.9 (0.7) 1.9 (0.6)
  F, df 5.9; 1,134a 7.03; 1,134b
Relatives group
Social network support in emergencies, r value − .27a − .34c
Help to patient in daily activities and care, r value .65d .58d
Duration of symptoms, r value 66d .58d
Relatives’ sex, mean (sd)
  Male – 1.7 (0.6)
  Female – 2.1 (0.7)
  F, df – 5.1; 1,  67a
ATTRv type, mean (sd)
  PN – 2.1 (0.7)
  CM – 1.5 (0.5)
  F, df – 7.2; 1,  67b
Page 8 of 11Magliano et al. Orphanet J Rare Dis          (2021) 16:163 
the national ATTRv Registry, it will be possible to con-
duct follow-up reassessment examining the burden in 
relation to the disease course. The replication of this 
study in countries with different health policies could be 
facilitated by the use of validated questionnaires avail-
able in different languages [25] and in patient and family 
versions.
The study revealed both similarities and differences 
in burden and in resources in patients with ATTRv and 
their relatives. In both groups, constraints of leisure 
activities are the practical consequences of the patient’s 
illness most frequently reported as present in the past 
2 months (72.30% and 60.9%). These limitations—also 
found in other disabling diseases—can negatively affect 
the social life of the whole family [10, 11, 13]. This situ-
ation can be particularly unfavorable in elderly patients, 
due to the spontaneous decline of social networks in old 
age. It is noteworthy that only 5.8% of patients reported 
frequent economic difficulties due to their medical con-
dition. This result is probably related to Italian health leg-
islation that guarantees all citizens free access to public 
health services [28].
As far as the psychological consequences are con-
cerned, worries for the future of other family mem-
bers are high in both patients and relatives (81.6% and 
75.0%). In addition, feeling of loss in thinking about the 
negative life changes that the illness has imposed on 
the patient are similarly reported by patients and family 
members (77.7% and 77.9%). These findings highlight 
that ATTRv has negative effects on relatives’ quality of 
life, a circumstance that sometimes may fuel feelings 
of frustration in patients [14]. The familiar hereditary 
influence of ATTRv is reflected in the feeling of guilt of 
a possibility to pass the disease to offspring, as found in 
the 58.2% of the patients and 39.5% of their relatives. 
Moreover, it is likely that feelings of loss and worries 
about the future—frequently reported by patients and 
relatives in this study—subtend fear of death, some-
times observed in patients with ATTRv and their at-
risk relatives [16, 17, 20]. Sixty-six percent of patients 
and 48.5% of family members were convinced that if 
the patient had not been ill everything would have 
been fine in their family. This conviction further out-
lines the feeling of guilt in these patients. Sixty percent 
of patients and key relatives stated they cried or felt 
depressed in the past 2 months. These findings are in 
line with those reported by Lopes et al. [16] about the 
prevalence of psychiatric problems in ATTRv patients 
and by Theaudin et  al. [12] on marital difficulties and 
depression in this disease. Feelings of sadness may lead 
to depression and other minor psychiatric disorders 
[18]. These findings emphasize the importance of pro-
viding psychological support to the entire family when 
necessary.
In both patients and key relatives, the subjective bur-
den is higher than the objective burden. This finding is 
in line with previous studies on long-term diseases [10, 
11] and it highlights that psychological consequences 
can be heavy even when the practical help needed by 
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Fig. 2 Paired sample comparisons of burden and support in patients with ATTRv and their relatives (N:69). Black square, patients; grey square, 
key-relatives. Paired sample t-test. NS, not significant
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noted that 57.5% of the patient sample was in condi-
tions of functional autonomy (FAP stage 0-1), being 
able to walk without help.
Analyses on matched patient-relative pairs revealed 
that practical difficulties are significantly higher among 
patients than relatives, whereas psychological difficul-
ties are similar in the two groups. This result highlights 
how the psychological consequences of the disease on 
key relatives can be substantial even when the practical 
family burden is lower than that faced by the patient. It 
is likely that aspects such as concern about the outcome 
of the disease, previous family experience of parents or 
siblings of the devastating effects of the disease and the 
meaning of ATTRv in the family relationships affect the 
overall level of psychological difficulties of the patient as 
well as his/her relative. It should also be noted that most 
relatives were spouses with an average age of 60.9 years 
(9.1 sd). It is likely that providing practical help to the 
patient can be a considerable physical strain for relatives 
of that age.
Most patients and family members had adequate 
information about the disease (87.9% and 72.1%) and 
treatment (85.6% and 77.9%) from physicians. In addi-
tion, about 35% of the sample participated in sessions 
dedicated to information about ATTRv. While education 
on the illness and treatments were guaranteed to most 
patients and their families, a very small percentage (2.9% 
and 3.0%) received psychological support from profes-
sionals. The lack of psychological support is an unmet 
need and was recommended among the suggestions to 
improve the quality of life by 22.9% of patients and 37.5% 
of their relatives, respectively. The lack of psychological 
support—common in physical and mental pathologies 
[10, 11, 13]—is partly explained by the lack of attention 
paid to the psychological aspects of care in the medi-
cal training, and the poor integration between medicine 
and health psychology. However, reluctance of patients 
and families to seek psychological support due to stigma 
mechanisms cannot be excluded [15]. Furthermore, 
the study revealed that compared to their key relatives, 
patients stated that they could rely on greater support 
from professionals and their social networks, suggesting 
greater solitude in caregivers than in the patients.
The study has some limitations that should be taken 
into account in the interpretation of the results. One 
limitation is that the study sample includes only symp-
tomatic individuals. Therefore, the results of this study 
cannot be generalized to asymptomatic patients and their 
relatives that may present different levels of psychological 
burden related to worries about the unfavorable outcome 
of the disease [13]. Other limitations are the lack of infor-
mation on whether the key-relative is an asymptomatic 
carrier and the potential commitment of participants in 
caregiving for other relatives in the past [17]. Moreover, 
the study did not examine the burden on non-key rela-
tives that could be as high as that of the key relative [29]. 
Furthermore, the study included only patients living with 
at least one adult relative. Therefore, the study did not 
explore the burden in patients receiving daily assistance 
by formal caregivers (i.e., persons paid for providing 
care). This condition may influence the burden perceived 
by the patients (for example, it can be associated to 
higher sense of loneliness) as the burden on non-cohab-
iting family members (for example, it can be associated 
with lower levels of family difficulties in social and work 
activities and with higher economic costs). Another limi-
tation is the lack of a control group which makes it diffi-
cult to interpret the results. An approximate comparison 
of burden experienced by ATTRv relatives with a previ-
ously tested sample of 120 key-relatives of adult patients 
in charge to specialized units for brain disorders [10] by 
using the same questionnaire, revealed similar levels of 
objective burden in the two sample (brain disorders fam-
ily objective burden: mean ± sd: 2.2 ± 0.7, t = 1.15, df 
259, p < .25) and higher levels of subjective burden in the 
brain disorders sample (2.4 ± 0.6, t = 3.68, df 259, p < 
.0003). Another approximate comparison of burden in 
relatives of patients with ATTRv with that experienced 
by 502 key-relatives of 4–25 years-old patients with 
muscular dystrophies [11] using the same questionnaire 
revealed statistically significant differences between the 
two samples. In particular, both objective and subjec-
tive burden were higher among the relatives of ATTRv 
patients than among the relatives of patients with mus-
cular dystrophies (objective burden: 1.6 ± 0.6, t = 8.42, 
df 641, p < .0001; subjective burden: 1.9 ± 0.6, t = 3.37, 
df 641, p < .0008). Results from the above-mentioned 
comparisons suggest that burden is a complex phenom-
enon in which variables related to the type of pathology 
and its outcome interact with variables related to the 
relationship between patient and relative. A further lim-
itation is that only 69 out of 141 expected key-relatives 
participated in the survey. The 51% refusal rate may have 
inflated the results on the average family burden which 
may in fact be lower in case of more autonomous patients 
who did not need to be accompanied to clinical visits 
(daily help needed by the non-accompanied patients, 
mean score ± sd: 1.6 (1.1) vs. accompanied patients: 2.0 
(1.0). It is likely that the 51% refusal rate also depends on 
the fact that in this group more often the patients were 
unmarried (36.4% vs. 14.5%).
Conclusions
Overall, the results of this study show that ATTRv is 
a disease affecting quality of life of both patients and 
their families. Supporting interventions should be 
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guaranteed to patients, to facilitate their adaptation 
to the disease, and to their families, to cope as best as 
possible with the difficulties that this pathology may 
involve. Family support should include: providing step-
by-step information on ATTRv and currently available 
treatments to patients and their informal caregivers; 
using a problem-solving approach to help patients and 
family members cope with the practical difficulties 
associated with the disease; and, encouraging patients 
and relatives to share their experience and seek mutual 
support, for example by joining self-help groups and 
patient and relative associations.
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